PH Form 144 Filed for 588-Share Sale via UBS on NYSE
Rhea-AI Filing Summary
Parker-Hannifin Corporation submitted a Form 144 reporting a proposed sale of 588 shares of common stock through UBS on the NYSE, with an aggregate market value of $429,342 and 127,778,004 shares outstanding. The securities were acquired via a SAR exercise and paid by wire on 08/08/2025, and the filer reports no other sales in the past three months.
This notice is a routine insider sale disclosure of a single, small transaction. The quantity reported is a very small portion of the company’s outstanding stock, and the filing primarily serves to document the planned sale and the method of acquisition and payment.
Positive
- Transparent disclosure: Form 144 documents the proposed sale of 588 shares through UBS on the NYSE.
- Clear acquisition and payment details: Securities were acquired via a SAR exercise and paid by wire on 08/08/2025.
Negative
- None.
Insights
TL;DR: Insignificant insider sale reported — 588 shares totalling $429,342; unlikely to move markets.
The Form 144 discloses a single proposed sale of 588 common shares with an aggregate market value of $429,342 executed through UBS on the NYSE. The securities were acquired via a SAR exercise and paid by wire on 08/08/2025. Given the reported 127,778,004 shares outstanding and no other sales in the past three months, this filing represents routine insider liquidity rather than a material capital event. Investors should view this as a transparency disclosure without immediate implications for the company’s capital structure or earnings.
TL;DR: Form 144 reflects compliance with insider-sale reporting requirements; no recent aggregated insider sales reported.
The filing documents compliance with Rule 144 by identifying the broker (UBS Financial Services), the exchange (NYSE), the acquisition method (SAR exercise), and payment details (wire). The filer attests to lacking undisclosed material adverse information. With no reported sales in the prior three months, this notice appears to be a single, compliant disclosure rather than part of a broader insider selling program.